chadox2 rabg
Vaccineexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 30, 2019 (NCT04162600)
Timeline
Indications
Studied for
Mechanism of action
- Lyssavirus rabiesImmunity, active
Lyssavirus rabies immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07168018 | Phase 2 | Dec 31, 2025 | University of Oxford |
| NCT04270838 | Phase 1 | Apr 30, 2020 | Ifakara Health Institute, University of Oxford |
| NCT04162600 | Phase 1 | Nov 30, 2019 | University of Oxford |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Oxford | Academic/Hospital | 3 | 3 | 2 | 2019 |
| Ifakara Health Institute | Academic/Hospital | 1 | 0 | 1 | 2020 |
2 organizations
Page 1 / 1